Clinical Trial Update: To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating QL2109 in combination with DARZALEX FASPRO for multiple myeloma is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))
• QL2109 (daratumumab biosimilar)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Multiple Myeloma | Phase 3 | Status: NOT_YET_RECRUITING